ArticleCurrent urology reports2008
The effects of reformulation: improved therapeutic index.
Article in Current urology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.European journal of clinical pharmacology · 2010Trial
- Recent advances in management of bladder overactivity.F1000 medicine reports · 2010Article
- The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.Reviews in urology · 2009Article
- The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.Reviews in obstetrics & gynecology · 2009Article
- Will the evolution of overactive bladder delivery systems increase patient compliance?Reviews in urology · 2009Article
- Defining efficacy in the treatment of overactive bladder syndrome.Reviews in urology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimuscarinic agents are the treatment of choice for overactive bladder syndrome. Due to the development of novel delivery systems, extended-release formulations of oxybutynin, tolterodine, and trospium chloride are now available. In addition to the convenience of once-daily dosing, the new formulations of these commonly prescribed agents have improved their therapeutic index, striking a better balance between efficacy and tolerability.
Indexed as
Identifiers
18947511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.